Skip to main content

Table 1 Demographics and baseline disease characteristics

From: Expression of the luteinizing hormone receptor (LHR) in ovarian cancer

Total Patients232100%
Surgery done08/02/91–12/13/12 
Age at Diagnosis
 < 6013056%
 ≥ 6010244%
Median (Range)58 (26–89) 
 Tumor Histology
 Serous Carcinoma16069%
 Endometrioid Adenocarcinoma219%
 Clear Cell Carcinoma177%
 Mixed156%
 Mucinous Carcinoma136%
 MMMT42%
 Undifferentiated21%
Pathologic Stage
 I5022%
 II188%
 III14060%
 IV2410%
Silberberg’s Grade
 12712%
 22812%
 317776%
Received Chemotherapy
 No167%
 Yes21693%
Residual Disease
 No11349%
 Yes11951%
Persistent Disease
 No14462%
 Yes8838%
LHR-I
 Negative3013%
 Weak2410%
 Moderate2611%
 Strong15266%
LHR-P
 0%3013%
 1–50%42%
 >  50%19785%
Missing/LHR Intensity Negative1 
Tumor HistologyNLHR Expression Intensity
NegativeWeakModerateStrong
Serous Carcinoma16016 (10%)19 (12%)16 (10%)109 (68%)
Endometrioid Adenocarcinoma213 (14%)2 (10%)3 (14%)13 (62%)
Clear Cell Carcinoma170 (0%)0 (0%)4 (24%)13 (76%)
Mixed154 (27%)1 (7%)3 (20%)7 (47%)
Mucinous Carcinoma136 (46%)2 (15%)0 (0%)5 (38%)
MMMT41 (25%)0 (0%)0 (0%)3 (75%)
Undifferentiated20 (0%)0 (0%)0 (0%)2 (100%)